| Today’s Big NewsJul 11, 2025 |
| By Nick Paul Taylor The FDA has rejected Capricor Therapeutics’ filing for approval of a Duchenne muscular dystrophy cell therapy, raising questions about whether the agency's new leadership may be rowing back from some of the flexibility shown by the old regime. Capricor’s share price fell 38% to $7.11 in premarket trading. |
|
|
|
By Gabrielle Masson Karyopharm Therapeutics is laying off 20% of staffers as efforts to secure a strategic alternative have turned up short. |
By James Waldron,Fraiser Kansteiner Although many of the complete response letters uploaded by the FDA this week have been subtly disclosed in drug approval packages over the years, the consolidation of the rejection notices offers an in-depth view into the high-stakes discussions that decide whether a medicine will ever make it to market. |
Sponsored by SAP and Answerthink Leaders discuss how built-in best practices and automation streamline growth for lean life sciences teams |
|
- Is your process truly scalable, efficient and validation-ready?
- Can your supply chain and manufacturing scale flex as your needs evolve?
- Do you have the manufacturing capacity to deliver when demand takes off?
Speak with Lonza’s experts and get answers that drive smarter decisions today. +(1)+(1)+(1).png)
|
|
By Darren Incorvaia,Zoey Becker Sally Susman, the communications chief who has shepherded Pfizer’s reputation and branding for more than 18 years, is departing the pharma giant at the end of the year amid its ongoing cost-cutting efforts. |
By Ayla Ellison,Gabrielle Masson,Andrea Park Biopharma layoffs have held steady through mid-2025, and in this episode of "The Top Line," we dig into the numbers, closures and policy changes shaping the trend. |
By Angus Liu After years spent upgrading its manufacturing capabilities, Pacira BioSciences figures it’s time to retire a facility that has been running for more than a decade. Along with it, 8% of the company’s workforce is also headed for the exit. |
By Zoey Becker Viatris, Hikma, Amneal, Apotex, Indivior, Sun Pharma, Alvogen and Zydus will together pay states and governments up to $720 million, according to press releases from state attorneys general. |
By Paige Minemyer UnitedHealth Group has announced further leadership appointments as returning CEO Stephen Hemsley solidifies his executive team. |
By Angus Liu China approved a first-in-class weight loss drug that Innovent Biologics licensed from Eli Lilly, Dizal won an FDA approval for a challenger to J&J's Rybrevant, while Biokin said a China phase 3 trial of its BMS-partnered bispecific ADC has met a primary endpoint. And more. |
Fierce podcasts Don’t miss an episode |
| Biopharma layoffs have held steady through mid-2025, and in this episode of "The Top Line," we dig into the numbers, closures and policy changes shaping the trend. |
|
|---|
|
|
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now. 
|
|
Whitepaper This white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
Whitepaper Presented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
Executive Summary Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| Sheraton Philadelphia Downtown |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
